← Leaderboards
Jeffrey J Olson
Emory University
$1,258,074
Attributed
$4,238,013
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $671.2K · FY2010–23$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,238,013 · 3
By mechanism
U01$3,171,477 · 1
R21$1,066,536 · 2
Top collaborators
- Xiaoping P Hu7 shared
- Hyunsuk Shim7 shared
- Peter B Barker5 shared
- Hui-Kuo Shu5 shared
Most similar at Emory University
Same institution · by research overlap
- Hyunsuk Shim$7,356,562
- Andrew H Miller$19,656,811
- Michael J Owens$5,654,463
- Donna J Toufexis$2,871,181
- Hui-Kuo Shu$1,642,136
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationTissuesOperative Surgical ProceduresNeuronsPre-ClinicalBaseInhibitor/AntagonistClinicImaging ModalityHistone DeacetylationBiopsyClassificationAlanineIncreased AppetiteGliomaImageDepressive SymptomsBehaviorBiochemicalCerebrumCerebrospinal FluidHistone Deacetylase InhibitorFundingCarcinogenesis
Grant awards (9)
Targeting Integrin Pathways by GLPG-0187 in Medulloblastoma$219,491
R21 · FY2023 · CA · contact PI
Targeting Integrin Pathways by GLPG-0187 in Medulloblastoma$182,909
R21 · FY2022 · CA · contact PI
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$617,130
U01 · FY2017 · CA
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$623,858
U01 · FY2016 · CA
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$632,744
U01 · FY2015 · CA
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$626,579
U01 · FY2014 · CA
Quantitative MRSI to predict early response to SAHA therapy in new GBM management$671,166
U01 · FY2013 · CA
Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma$327,011
R21 · FY2011 · CA
Using Proton MRS to Predict Response of SAHA treatment in Glioblastoma$337,125
R21 · FY2010 · CA